Miranka Wirth1, Gloria Benson2, Claudia Schwarz3, Theresa Köbe4, Ulrike Grittner5, Dietmar Schmitz6, Stephan J Sigrist7, Jens Bohlken8, Slaven Stekovic9, Frank Madeo10, Agnes Flöel11. 1. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Center for Stroke Research, Berlin, Germany. 2. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany. Electronic address: gloria.benson@charite.de. 3. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany. Electronic address: claudia.schwarz@charite.de. 4. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany; Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada. Electronic address: theresa.koebe@charite.de. 5. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany. Electronic address: ulrike.grittner@charite.de. 6. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany. Electronic address: dietmar.schmitz@charite.de. 7. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany; Institute for Biology/Genetics, Freie Universität Berlin, Berlin, Germany. Electronic address: stephan.sigrist@fu-berlin.de. 8. Medical Practice Bohlken for Neurology and Psychiatry, Berlin, Germany. Electronic address: dr.j.bohlken@gmx.net. 9. Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria; BioTechMed Graz, Graz, Austria. Electronic address: slaven.stekovic@uni-graz.at. 10. Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria; BioTechMed Graz, Graz, Austria. Electronic address: frank.madeo@uni-graz.at. 11. Department of Neurology, University Medicine Greifswald, Greifswald, Germany. Electronic address: agnes.floeel@uni-greifswald.de.
Abstract
INTRODUCTION:Nutritional intervention with the natural polyamine spermidine, an autophagy-enhancing agent, can prevent memory loss in aging model organisms. This is the first human study to evaluate the impact of spermidine supplementation on memory performance in older adults at risk for the development of Alzheimer's disease. METHODS:Cognitively intact participants with subjective cognitive decline (n = 30, 60-80 years of age) were included in this three-months, randomized, placebo-controlled, double-blind Phase IIa pilot trial with a spermidine-rich plant extract supplement. Effects of intervention were assessed using the behavioral mnemonic similarity task, measured at baseline and post-intervention visits. Data analysis was focused on reporting and interpreting effectiveness based on effect sizes. RESULTS:Memory performance was moderately enhanced in the spermidine group compared with placebo at the end of intervention [contrast mean = .17, 95% confidence interval (CI): -.01, .35, Cohen's d = .77, 95% CI: 0, 1.53]. Mnemonic discrimination ability improved in the spermidine-treated group with a medium effect size (mean difference = -.11, 95% CI: -.19, -.03, Cohen's d = .79, 95% CI: .01, 1.55). A similar effect was not found in the placebo-treated group (mean difference = .07, 95% CI: -.13, .27, Cohen's d = -.20, 95% CI: -.94, .54). DISCUSSION: In this pilot trial, nutritional spermidine was associated with a positive impact on memory performance in older adults with subject cognitive decline. The beneficial effect might be mediated by stimulation of neuromodulatory actions in the memory system. A follow-up Phase IIb randomized controlled trial will help validate the therapeutic potential of spermidine supplementation and delineate possible neurophysiological mechanisms of action. TRIAL REGISTRATION: Registered in ClinicalTrials.gov with the Identifier NCT02755246.
RCT Entities:
INTRODUCTION: Nutritional intervention with the natural polyamine spermidine, an autophagy-enhancing agent, can prevent memory loss in aging model organisms. This is the first human study to evaluate the impact of spermidine supplementation on memory performance in older adults at risk for the development of Alzheimer's disease. METHODS: Cognitively intact participants with subjective cognitive decline (n = 30, 60-80 years of age) were included in this three-months, randomized, placebo-controlled, double-blind Phase IIa pilot trial with a spermidine-rich plant extract supplement. Effects of intervention were assessed using the behavioral mnemonic similarity task, measured at baseline and post-intervention visits. Data analysis was focused on reporting and interpreting effectiveness based on effect sizes. RESULTS: Memory performance was moderately enhanced in the spermidine group compared with placebo at the end of intervention [contrast mean = .17, 95% confidence interval (CI): -.01, .35, Cohen's d = .77, 95% CI: 0, 1.53]. Mnemonic discrimination ability improved in the spermidine-treated group with a medium effect size (mean difference = -.11, 95% CI: -.19, -.03, Cohen's d = .79, 95% CI: .01, 1.55). A similar effect was not found in the placebo-treated group (mean difference = .07, 95% CI: -.13, .27, Cohen's d = -.20, 95% CI: -.94, .54). DISCUSSION: In this pilot trial, nutritional spermidine was associated with a positive impact on memory performance in older adults with subject cognitive decline. The beneficial effect might be mediated by stimulation of neuromodulatory actions in the memory system. A follow-up Phase IIb randomized controlled trial will help validate the therapeutic potential of spermidine supplementation and delineate possible neurophysiological mechanisms of action. TRIAL REGISTRATION: Registered in ClinicalTrials.gov with the Identifier NCT02755246.
Authors: Pratishtha Chatterjee; Anne M Fagan; Chengjie Xiong; Matthew McKay; Atul Bhatnagar; Yunqi Wu; Abhay K Singh; Kevin Taddei; Ian Martins; Samantha L Gardener; Mark P Molloy; Gerhard Multhaup; Colin L Masters; Peter R Schofield; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Marieke J H Wermer; Mark A van Buchem; Hamid R Sohrabi; Ralph N Martins Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Cassandra E Holbert; Matthew Dunworth; Jackson R Foley; Tiffany T Dunston; Tracy Murray Stewart; Robert A Casero Journal: J Biol Chem Date: 2020-05-19 Impact factor: 5.157
Authors: Bruna A Girardi; Shaiana Fabbrin; Arithane L Wendel; Carlos F Mello; Maribel A Rubin Journal: Psychopharmacology (Berl) Date: 2019-12-11 Impact factor: 4.530
Authors: Julian M Gaitán; Hyo Youl Moon; Matthew Stremlau; Dena B Dubal; Dane B Cook; Ozioma C Okonkwo; Henriette van Praag Journal: Front Endocrinol (Lausanne) Date: 2021-05-20 Impact factor: 5.555
Authors: Thomas Pekar; Katharina Bruckner; Susanne Pauschenwein-Frantsich; Anna Gschaider; Martina Oppliger; Julia Willesberger; Petra Ungersbäck; Aribert Wendzel; Alexandra Kremer; Walter Flak; Felix Wantke; Reinhart Jarisch Journal: Wien Klin Wochenschr Date: 2020-11-19 Impact factor: 1.704